//
you're reading...
Noticias

J&J prostate cancer drug improves survival

Johnson & Johnson’s prostate cancer drug Zytiga improved survival in patients who have not received chemotherapy in a late-stage study.

An independent data monitoring committee recommended that patients receiving a placebo in the trial be offered treatment with Zytiga, the company said in a statement.

Thursday’s data sent shares of Medivation Inc, which is also developing a prostate cancer pill that works by targeting the same hormone that Zytiga targets, up 9 percent.

However, shares of Dendreon Corp fell 16 percent. Dendreon makes a prostate cancer vaccine, Provenge, that has a different mechanism of action.

(Reporting by Kavyanjali Kaushik and Esha Dey in Bangalore; Editing by Gopakumar Warrier)

Comentarios

Los comentarios están cerrados.

Dolar hoy

24 hs gold price [Most Recent Quotes from www.kitco.com] Franco Suizo las 24 hs [Most Recent Exchange Rate from www.kitco.com] Yen las 24 hs [Most Recent Exchange Rate from www.kitco.com] Euro las 24hs [Most Recent Exchange Rate from www.kitco.com] Libra 24 hs [Most Recent Exchange Rate from www.kitco.com] Cobre las 24 hs
[Most Recent Quotes from www.kitco.com]
A %d blogueros les gusta esto: